Carbocisteine



Combined with:

Indications and Reactions:

Role Indications Reactions
Secondary
Product Used For Unknown Indication 19.6%
Drug Use For Unknown Indication 13.3%
Prophylaxis 10.2%
Infection Prophylaxis 9.3%
Constipation 7.5%
Eczema 5.0%
Hypertension 4.3%
Compression Fracture 3.6%
Upper Respiratory Tract Inflammation 3.1%
Allergy Prophylaxis 2.9%
Dry Skin Prophylaxis 2.5%
Eczema Asteatotic 2.5%
Hypokalaemia 2.5%
Haemorrhoids 2.3%
Chronic Respiratory Failure 2.2%
Cough 2.2%
Pyrexia 2.0%
Trigeminal Neuralgia 1.8%
Hepatitis C 1.6%
Insomnia 1.6%
Urinary Retention 20.9%
Drug Interaction 7.5%
Infective Exacerbation Of Chronic Obstructive Airways Disease 7.5%
Cyanosis 6.0%
Pseudomembranous Colitis 6.0%
Toxic Epidermal Necrolysis 6.0%
Tubulointerstitial Nephritis 6.0%
Vomiting 6.0%
Renal Failure 4.5%
Anaphylactic Shock 3.0%
Death 3.0%
Drug Eruption 3.0%
Eosinophilia 3.0%
Rash 3.0%
Renal Impairment 3.0%
Stomatitis 3.0%
Supraventricular Tachycardia 3.0%
Tremor 3.0%
Apnoeic Attack 1.5%
Beta Haemolytic Streptococcal Infection 1.5%
Concomitant
Product Used For Unknown Indication 47.1%
Drug Use For Unknown Indication 14.1%
Chronic Obstructive Pulmonary Disease 4.5%
Bronchitis 4.5%
Rheumatoid Arthritis 3.3%
Asthma 3.0%
Hypertension 3.0%
Prophylaxis 3.0%
Pain 2.5%
Constipation 2.3%
Cough 1.8%
Depression 1.8%
Diabetes Mellitus 1.5%
Emphysema 1.4%
Retinal Detachment 1.3%
Insomnia 1.1%
Upper Respiratory Tract Inflammation 1.0%
Glycogen Storage Disease Type Ii 0.9%
Lower Respiratory Tract Infection 0.9%
Parkinson's Disease 0.9%
Water Intoxication 12.6%
Vomiting 8.3%
Pneumonia 7.4%
White Blood Cell Count Increased 7.0%
Wheezing 6.5%
Thrombocytopenia 6.1%
Treatment Failure 5.2%
Electrocardiogram Qt Prolonged 4.8%
Death 4.3%
Pyrexia 4.3%
Vocal Cord Paralysis 4.3%
Hallucination 3.9%
Malaise 3.5%
Renal Failure Acute 3.5%
Interstitial Lung Disease 3.0%
Nausea 3.0%
Oedema Peripheral 3.0%
Rash 3.0%
Sepsis 3.0%
Skin Exfoliation 3.0%
Interacting
Hypertension 46.2%
Mycobacterial Infection 30.8%
Atypical Mycobacterial Infection 23.1%
Drug Interaction 60.0%
Interstitial Lung Disease 20.0%
Lung Disorder 20.0%